Literature DB >> 10658059

Parietal cell vagotomy versus vagotomy-antrectomy: ulcer surgery in the modern era.

P E Donahue1.   

Abstract

Patients with peptic ulcer occasionally develop complications that require surgical intervention, despite the advances in medical treatment and changes in the natural history of disease. The clinical surgeon must make a decision about performing "selective vagotomy antrectomy versus highly selective vagotomy," based on the information discussed herein. The goals for operative treatment remain safe correction of the presenting problem, avoidance of perioperative morbidity and mortality, and freedom from disabling postoperative side effects. This paper addresses broad aspects of the details of surgical interventions; because most operative procedures are performed in urgent circumstances in patients who often have a variety of conditions, it is not surprising that there is no best operation suited to every complication of ulcer.

Entities:  

Mesh:

Year:  2000        PMID: 10658059     DOI: 10.1007/s002689910043

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  4 in total

Review 1.  Impact of gastric and bowel surgery on gastrointestinal drug delivery.

Authors:  Susan Hua; Ephraem C Lye
Journal:  Drug Deliv Transl Res       Date:  2022-05-18       Impact factor: 4.617

2.  Surgical management of complicated ulcer disease.

Authors:  Ronald F Martin; Steven W Bang
Journal:  Curr Treat Options Gastroenterol       Date:  2007-04

3.  Trends and predictors for vagotomy when performing oversew of acute bleeding duodenal ulcer in the United States.

Authors:  Brian C Reuben; Greg Stoddard; Robert Glasgow; Leigh A Neumayer
Journal:  J Gastrointest Surg       Date:  2007-01       Impact factor: 3.452

4.  Vagotomy during hiatal hernia repair: a benign esophageal lengthening procedure.

Authors:  Brant K Oelschlager; Kyle Yamamoto; Todd Woltman; Carlos Pellegrini
Journal:  J Gastrointest Surg       Date:  2008-05-08       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.